Subscribe
lost-my-umbrella
20 November 2013Americas

Teva to lose grip on Copaxone next year

The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
US court rules Teva patent invalid
30 July 2013   A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.
Americas
FDA approval adds new life to Copaxone
29 January 2014   On January 28, Teva announced that the FDA had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

article
US court rules Teva patent invalid
30 July 2013   A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.
Americas
FDA approval adds new life to Copaxone
29 January 2014   On January 28, Teva announced that the FDA had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.

More on this story

article
US court rules Teva patent invalid
30 July 2013   A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.
Americas
FDA approval adds new life to Copaxone
29 January 2014   On January 28, Teva announced that the FDA had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.

More features

Gene tech firm fends off injunction in test kit dispute
Comparing life sciences IP in Brazil and the US
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal